CASMI Translational Stem Cell Consortium Launch Event
On the 30th July 2013, international academic and industrial leaders gathered at the St James’ Club in Paris to grapple with key barriers to the effective and sustainable of stem cell based technologies: therapeutics, screening tools and targets. This was followed by a visit to I-Stem in Evry, France.
The following were amongst the key questions addressed:
What are the key deficiencies in existing iPSC and ESC standardization efforts, and how can we best act to harmonize these efforts?
Regulation and IP
Building on community experience with ASCs, what regulatory uncertainties remain with respect to ESCs and what additional uncertainties are perceived for iPSCs?
Which models for strategic partnerships are accelerating stem cell translation most effectively? And for those that are not, why not?
Failure to demonstrate sufficient efficacy represents a major barrier to the adoption of existing cellular therapeutics. What steps (and data) are required to confer stakeholder confidence and successful adoption?
What are the key outstanding challenges as we seek to remove the ‘art’ and cost from the manufacture of iPS therapies?
The transformative work of the CASMI Translational Stem Cell Consortium is supported by the Californian Institute for Regenerative Medicine (CIRM), TAP Biosystems, NIH Centre for Regenerative Medicine, SENS Research Foundation, Lonza, UK Cell Therapy Catapult, GE Healthcare and the Canadian Centre for the Commercialization of Regenerative Medicine (CCRM).
For further details please contact the Consortium Co-ordinator David Brindley
Email David Brindley.